Abstract
BackgroundInterstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). Current guidelines consider that some patients may not require pharmacological treatment. To date, the characteristics and...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have